资讯
Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...
The company’s shares jumped 13.3% as the results of the trial, the first of several under way on the pill, orforglipron, ...
Lilly shares surged about 14 per cent after the results of the study emerged. US-listed shares of Ozempic maker Novo, down more than 50 per cent over the past year, dipped again on Thursday.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果